BRIDGEWATER, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences:

• The Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, October 1, 2018 at 4:40 p.m. ET.
• The Leerink Partners Roundtable Series: Rare Disease & Oncology in New York City on Tuesday, October 2, 2018 at 1:30 p.m. ET.

These presentations will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcasts will be archived for a period of 90 days following the conclusion of each live event.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE^® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.  For more information, visit www.insmed.com.

Contact:
Blaine Davis
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.